Drugs / ZL-1109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07211776 | Dec 2025 → Mar 2027 expected | endocrine exophthalmos | Zai Lab (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-1109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07211776 ↗ |
| Known as | VRDN-003 | “ZL-1109 (VRDN-003)” NCT07211776 ↗ |
| Route | Subcutaneous | “ZL-1109 subcutaneous injection” NCT07211776 ↗ |